Hatch Bio Fund

翰长生物医疗（深圳）有限公司

致力于通过人工智能、远程诊断和医疗技术，与全球专业健康服务者一起，共同提升人类健康水平。

翰长生物医疗（深圳）有限公司

致力于通过人工智能、远程诊断和医疗技术，与全球专业健康服务者一起，共同提升人类健康水平。

Vittoria Biotherapeutics, Inc.

Clinical-stage immunotherapy company developing novel CAR T cell therapies using the Senza5™ platform for solid tumors and autoimmune diseases, licensed from University of Pennsylvania.

Latus Bio

Patient-centric gene therapy company developing proprietary AAV capsids screened in non-human primates for clinical administration, founded from Professor Beverly Davidson's lab.

MasterSwitch Bio

Joint spinout from University of Pittsburgh and University of Pennsylvania developing modified mRNA therapy targeting HNF4α for End Stage Liver Disease with cirrhosis; co-founded by Nobel laureate Dr. Drew Weissman.

Ladder Bio (formerly ThirdLaw Molecular)

Spinout from Temple University creating synthetic Spiroligomers™—orally available, cell-permeable peptide-like molecules—for selective protein binding across diverse targets.

Hula Therapeutics

Immunotherapy spin-out from Children’s Hospital of Philadelphia; identifies tumor-essential, HLA-presented targets that are considered “undruggable” and engineers therapies to improve safety & efficacy in solid tumors.

Helix

Ladder Bio

Spin-out from Temple University; developed a synthetic, modular, fused-ring peptide-like platform (“Spiroligomers™”) that is cell-permeable & orally bioavailable to engage challenging protein targets; billions of library members.

Genome Medical